PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
iRegene Receives IND approval from U.S. FDA to Start
WUHAN, China I June 24, 2024 I On June 20 (UTC-4), the U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson’s Disease.This marks a significant milestone as NouvNeu001 becomes the world’s first chemically induced allogeneic cell therapy product to enter clinical stages for Parkinson’s ...
UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab …
2024年9月23日 · With three new indications, BIMZELX ® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases ; Approval in active PsA is supported by two Phase 3 studies in which bimekizumab-bkzx showed statistically significant improvements vs. placebo at Week 16 in both joint and skin symptoms, across ...
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor …
BEIJING, China I January 16, 2024 I InnoCare Pharma (HKEX: 09969; SSE: 688428), a commercial-stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company’s B-cell lymphoma-2 (BCL2) inhibitor, ICP-248. This is InnoCare’s fifth innovative drug to enter the clinical stage in the U.S.
MEKanistic Therapeutics Inc.'s First-in-Class Dual EGFR and PI3K ...
2024年7月11日 · New MTX-531 Research in Nature Cancer Highlights Promising Dual Inhibitor Strategy for Overcoming Cancer Resistance. MINNEAPOLIS, MN, USA I July 11, 2024 I MEKanistic Therapeutics Inc., a biotechnology company pioneering the development of next-generation kinase inhibitors for cancer treatment, today announced the peer-reviewed publication of new preclinical research on its lead candidate, MTX ...
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A …
2024年7月25日 · PARSIPPANY, NJ, USA & PARIS, France I July 25, 2024 I Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
Agomab Starts Phase 1 Clinical Study for AGMB-447 in
2023年12月14日 · AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 . GHENT, Belgium I December 14, 2023 IAgomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in ...
Ascletis Enters the Obesity Drug Space with Announcement of …
2024年9月18日 · Small Molecules. Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once …
Lilly and Innovent Biologics Expand Their Strategic Alliance to …
2015年10月12日 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Tune Therapeutics Presents First Data Supporting TUNE-401: a …
2023年12月7日 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …